New therapy with XLQ® to suppress chronic prostatitis through its anti-inflammatory and antioxidative activities.

Chronic prostatitis is a common urological disease. The etiology of this disease and effective therapy for its treatment are yet to be elucidated. We investigated the functions of XLQ® in chronic nonbacterial prostatitis using a complete Freund's adjuvant-induced rat model. Prostates and blood samples were collected for further evaluation after oral gavage with XLQ ® or a vehicle for 4 weeks. The results showed that XLQ ® significantly decreased the prostate index, ameliorated the histopathologic changes, and reduced CD3+ and CD45+ cell infiltration in the prostate stroma. Further study showed that XLQ ® suppressed the expression of proinflammatory cytokines, such as interleukin (IL)-1β, IL-2, IL-6, IL-17A, monocyte chemoattractant protein-1, and tumor necrosis factor-α. XLQ ® showed a strong antioxidant capacity by enhancing the activities of antioxidative enzymes (e.g., total superoxide dismutase, catalase, and glutathione peroxidase) and decreasing the level of lipid peroxidation products (malondialdehyde). Moreover, XLQ ® can suppress the activation of nuclear factor-κB and P38-mitogen-activated protein kinase signaling pathways. In summary, XLQ ® has affirmative effects on chronic prostatitis, which could be attributed to its anti-inflammatory and antioxidative capacities. On the basis of these results, XLQ ® can be developed as an effective and safe therapy for chronic prostatitis.

Journal of cellular physiology. 2019 Feb 20 [Epub ahead of print]

Feiya Yang, Lingquan Meng, Panpan Han, Dexi Chen, Mingshuai Wang, Yongguang Jiang, Yanqiao Wu, Yiling Wu, Nianzeng Xing

Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China., Department of Urology, Qianfoshan Hospital, Shandong University, Jinan, P. R. China., Department of Hematology, Qilu Hospital, Shandong University, Jinan, P. R. China., Department of Hepatology, Beijing You'an Hospital, Capital Medical University, Beijing, P. R. China., Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P. R. China., Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing, P. R. China., National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang Yiling Pharmaceutical Co., Ltd, Shijiazhuang, P. R. China.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe